Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a year-end business update on its pipeline of small molecules for the treatment of retinal diseases.Key fourth-quarter, full-year 2025, and recent corporate highlights include:Advanced KIO-301 from regulatory clearance to patient dosing in ABACUS-2, a Phase 2 randomized, c ...